var data={"title":"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">H Richard Alexander, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 16, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Malignant mesothelioma is a highly lethal malignancy of the serosal membranes of the pleura, peritoneum, pericardium, or tunica vaginalis testes. This is a rare disease. As an example, of the approximately 3300 cases of mesothelioma diagnosed in the United States every year, only 10 to 15 percent are peritoneal [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1-4\" class=\"abstract_t\">1-4</a>]. The peritoneum is the second most frequent site of origin of mesothelioma, following the pleura. The pathogenesis of all forms of mesothelioma is strongly associated with industrial pollutants, of which asbestos is the principal carcinogen associated with the disease. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H3\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Asbestos exposure'</a>.)</p><p>Malignant peritoneal mesothelioma (MPM) is an understudied disease, largely because most molecular and clinical studies have been conducted predominantly in patients with the more common pleural variant. However, it is not clear that the two diseases are similar. While they share the same predominant risk factor (asbestos exposure), gene expression profiles of pleural and peritoneal mesotheliomas are distinct, suggesting differences in molecular pathogenesis between the two [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p>This topic review will cover the epidemiology, histology, clinical features, diagnosis, and staging of MPM. Treatment of MPM and the epidemiology, pathology, clinical presentation, diagnosis, and staging of pleural, pericardial, and testicular mesothelioma are presented elsewhere. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;</a> and <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;</a> and <a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma&quot;</a> and <a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Initial management of malignant pleural mesothelioma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY AND RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, malignant peritoneal mesothelioma (MPM) accounts for approximately 10 to 15 percent of all cases of mesothelioma, and there are approximately 400 new cases diagnosed annually [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Mesothelioma rates are rising worldwide, largely a reflection of occupational asbestos exposure [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1,4,7,8\" class=\"abstract_t\">1,4,7,8</a>]. The incidence is expected to peak between 2015 and 2025 [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/9\" class=\"abstract_t\">9</a>]. However, pleural mesothelioma accounts for most of the rising number of cases. At least in the United States, incidence rates of MPM have remained stable over the last 30 years [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4,10\" class=\"abstract_t\">4,10</a>]. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;</a>.)</p><p>In contrast to pleural mesothelioma, which has a male predominance (male to female ratio of between four and five to one), men comprise a smaller proportion of cases of MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1,2,4,11\" class=\"abstract_t\">1,2,4,11</a>]. </p><p>As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 10,589 cases of mesothelioma reported to the Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2005, 44 percent of the 1112 peritoneal cases arose in women as compared with 19 percent of the 9211 pleural primaries [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4\" class=\"abstract_t\">4</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a meta-analysis of 20 articles reporting on 1047 patients who underwent surgical resection and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of MPM, 59 percent were female [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p>The higher proportion of females who develop MPM is generally interpreted to reflect a higher background rate of mesothelioma that is unrelated to asbestos exposure [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1,13\" class=\"abstract_t\">1,13</a>]. (See <a href=\"#H4\" class=\"local\">'Asbestos'</a> below.)</p><p>The median age at presentation is 51 to 59, younger than that of the average patient with pleural mesothelioma [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4,12,14,15\" class=\"abstract_t\">4,12,14,15</a>]. Although MPM is typically a disease of adults, childhood cases have been reported [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/16-18\" class=\"abstract_t\">16-18</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Risk factors</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Asbestos</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a strong relationship between asbestos exposure and the development of mesothelioma at any location. The lifetime risk of developing mesothelioma among asbestos workers is thought to be as high as 10 percent, and the latency period between exposure and the development of mesothelioma is approximately 20 to 40 years [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/19,20\" class=\"abstract_t\">19,20</a>]. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H3\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Asbestos exposure'</a>.)</p><p>However, the link between exposure to asbestos and MPM is less strong than it is for pleural mesothelioma, particularly among women [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13,21-23\" class=\"abstract_t\">13,21-23</a>]. In a population-based study that was based upon telephone interviews of mesothelioma cases and controls, the attributable risk for exposure to asbestos was 58 percent for peritoneal and 88 percent for pleural mesothelioma among men, and 23 percent for both types among women [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13\" class=\"abstract_t\">13</a>]. The reason for this gender difference is unclear, but misclassification of exposure history in women may be in part responsible. </p><p>Nevertheless, asbestos is the best defined risk factor for MPM, as reflected by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In cohorts of workers exposed to asbestos, MPM was responsible for 0.1 to 1 percent of all deaths [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The role of occupational asbestos exposure in causing MPM was confirmed in several community-based studies [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13,20,24\" class=\"abstract_t\">13,20,24</a>]. In one, the odds ratio of a peritoneal cancer was 180 (95% CI 23.5-1375) for insulation workers and 7.6 (95% CI 2.3-25.5) for manufacturers of nonmetallic mineral products, including asbestos.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two studies provide evidence for an increased risk of MPM with non-occupational (ie, household or residential) exposure [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p/><p>MPM induced by asbestos generally requires a higher cumulative dose than its pleural counterpart [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/27-29\" class=\"abstract_t\">27-29</a>]. The risk of MPM is proportional to the square of cumulative exposure, while the risk of pleural mesothelioma rises less than linearly with the cumulative asbestos dose [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/27\" class=\"abstract_t\">27</a>]. Thus, the risk of pleural mesothelioma appears to rise more steeply at low levels of exposure, while at higher levels of exposure, peritoneal tumors predominate.</p><p>This concept can be illustrated by an early study examining the relative risk (RR) of developing pleural or peritoneal mesothelioma based upon the type of occupation [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/28\" class=\"abstract_t\">28</a>]. Relative risks (RRs) ranged from 2.6 in construction workers to 46.1 in insulation workers. Occupations with the highest overall RR had a higher proportion of peritoneal primaries. In fact, 44 percent of the mesotheliomas that arose in these groups were peritoneal. The biologic basis underlying this observation is not understood.</p><p>The main fiber type implicated in the United States is amosite (an amphibole); in contrast to pleural mesothelioma, chrysotile has not been convincingly shown to cause MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H3\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Asbestos exposure'</a>.)</p><p>It has been shown that a tumor suppressor gene previously identified in pleural mesothelioma, <em>BAP1</em>, is frequently mutated in MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/30\" class=\"abstract_t\">30</a>]. Others have shown an increased susceptibility to MPM in germline <em>BAP1</em> heterozygous mice [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/31\" class=\"abstract_t\">31</a>], leading to speculation that patients with <em>BAP1</em> mutations may have a predisposition to develop malignant mesothelioma after environmental exposure to asbestos. (See <a href=\"#H1274984149\" class=\"local\">'Molecular pathogenesis'</a> below.) </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Radiation therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although asbestos exposure is the predominant defined risk factor, there are also case reports of MPM arising in irradiated fields, although the number is small overall, and the magnitude of the risk is undefined [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/32-34\" class=\"abstract_t\">32-34</a>]. The association between radiation exposure and mesothelioma was investigated in a longitudinal analysis of long-term solid cancer survivors derived from the SEER database [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/35\" class=\"abstract_t\">35</a>]. They found a modest increased risk of developing peritoneal mesothelioma in cancer patients who received direct peritoneal external beam radiation, but not in those who received scattered radiation delivered to other areas. Overall, the clinical impact of radiation exposure on the development of peritoneal mesothelioma is limited. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H4\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Radiation'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Exposure to other mineral fibers (eg, erionite, a silicate fiber of the zeolite family) is reported to be a risk factor for peritoneal as well as pleural mesothelioma [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H3\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Asbestos exposure'</a>.) </p><p>MPM has been reported in three separate cohorts of patients who received thorotrast for radiological examinations [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/37-39\" class=\"abstract_t\">37-39</a>]. The cumulative incidence of MPM in these series is 0.2 to 0.6 percent, higher than that seen in many cohorts of asbestos-exposed workers. (See <a href=\"#H4\" class=\"local\">'Asbestos'</a> above.)</p><p>A large number of pleural mesotheliomas contain sequences of the papovavirus, simian virus 40 (SV40), and this has been seen in peritoneal mesothelioma as well. In one study, 7 of 11 German cases of MPM were positive for SV40 sequences [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/40\" class=\"abstract_t\">40</a>]. However, the causal nature of this association has been questioned, and laboratory contamination may explain some of the findings [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma#H6\" class=\"medical medical_review\">&quot;Epidemiology of malignant pleural mesothelioma&quot;, section on 'Viral oncogenes'</a>.)</p><p>Cases of MPM have also been reported in the setting of chronic peritonitis [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/42,43\" class=\"abstract_t\">42,43</a>], and an increased risk of MPM has been associated with a diet low in vegetable consumption [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H1274984149\"><span class=\"h1\">MOLECULAR PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The molecular pathogenesis of peritoneal mesothelioma is largely unknown. However, this is an area of active research:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It has been shown that a tumor suppressor gene previously identified in pleural mesothelioma, <em>BAP1</em>, is frequently mutated in malignant peritoneal mesothelioma (MPM) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/30\" class=\"abstract_t\">30</a>]. One study has shown that patients with <em>BAP1</em> mutations have improved survival compared with those without them; this association is independent of histological type, age, or gender [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A group from Pittsburgh has analyzed various genetic alterations in almost 90 patients with MPM and identified homozygous cyclin-depended kinase inhibitor 2A (CDKN2A) deletions in 29 percent, hemizygous neurofibromin 2 (NF2) loss in 35 percent, and loss of BAP1 protein expression in 79 percent [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/46\" class=\"abstract_t\">46</a>]. Combined CDKN2A deletion and NF2 loss was a negative prognostic factor for both progression-free and overall survival, independent of other known prognostic factors, including patient age, peritoneal cancer index, completeness of cytoreduction, and extent of invasion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, 11 of 88 patients (13 percent) with peritoneal mesothelioma were found to have anaplastic lymphoma kinase (<em>ALK</em>) gene rearrangements in tumors tested by immunohistochemistry or fluorescent in situ hybridization [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/47\" class=\"abstract_t\">47</a>]. Loss of chromosomal region 9p or 22q, or genetic alterations in <em>BAP1</em> or <em>NF2</em> that are typically identified in peritoneal mesothelioma were not observed in <em>ALK</em>-rearranged tumors. ALK-positive tumors were more likely in women and younger patients than in those without <em>ALK</em> rearrangements, but other parameters, including survival, were not different between groups.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CLINICAL PRESENTATION AND IMAGING FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no signs or symptoms that are specific for malignant peritoneal mesothelioma (MPM). Although most cases are symptomatic, a few are diagnosed incidentally, after inquiry into an unrelated process, such as infertility, or recognized during a routine physical examination [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/48-50\" class=\"abstract_t\">48-50</a>]. In a review of 35 MPM patients treated at a single center, the most frequent symptoms were abdominal <span class=\"nowrap\">distention/pain,</span> weight loss, dyspnea, and chest pain. The average time between the onset of symptoms and diagnosis was approximately five months [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/15\" class=\"abstract_t\">15</a>].</p><p>The majority of cases of MPM present with diffuse peritoneal involvement and are variably referred to as diffuse peritoneal mesothelioma, MPM or just peritoneal mesothelioma. However, a minority of cases has localized disease, and they have a different presentation and natural history [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51,52\" class=\"abstract_t\">51,52</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse MPM is highly aggressive, with a few exceptions (such as the well-differentiated papillary mesotheliomas that occur in women). (See <a href=\"#H8237767\" class=\"local\">'Well-differentiated papillary mesothelioma'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast, patients with a localized MPM usually have a good prognosis following complete surgical excision. </p><p/><p class=\"headingAnchor\" id=\"H12630199\"><span class=\"h2\">Clinical features</span></p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Diffuse versus localized peritoneal mesothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations of diffuse MPM are related to ascites or tumor progression within the abdominal cavity [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/12,53,54\" class=\"abstract_t\">12,53,54</a>]. Common complaints include abdominal distention <span class=\"nowrap\">and/or</span> increasing abdominal girth, abdominal pain or discomfort, nausea, anorexia, and weight loss. Gastrointestinal complications such as bowel obstruction are usually a manifestation of advanced disease.</p><p>Due to the nonspecific nature of the presenting symptoms, many patients already have an advanced disease burden at diagnosis. A minority is asymptomatic and diagnosed incidentally, often as the result of a palpated abdominal mass [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/49,50\" class=\"abstract_t\">49,50</a>].</p><p>Abdominal distention (increased abdominal girth), the most frequent initial symptom, is present in 30 to 80 percent of patients [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/54,55\" class=\"abstract_t\">54,55</a>]. It can cause early satiety, dysphagia, and shortness of breath, all of which contribute to weight loss, impaired performance status, and overall inanition. Abdominal distension may also manifest as a new or worsening abdominal wall hernia, which, if subject to attempted surgical repair, may reveal the unsuspected diagnosis of a mesothelioma.</p><p>Most patients with abdominal distention due to excess energy intake or who develop progressive accumulation of ascites associated with nonmalignant conditions (eg, cirrhosis) gain weight. Decreasing weight associated with loss of lean body mass in a patient with progressively increasing abdominal girth should raise suspicion for malignant ascites secondary to a peritoneal surface malignancy. (See <a href=\"topic.htm?path=malignancy-related-ascites#H4\" class=\"medical medical_review\">&quot;Malignancy-related ascites&quot;, section on 'Clinical manifestations'</a>.)</p><p>Pain is the second most common initial symptom and is present at diagnosis in 27 to 58 percent of patients [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/49,55-57\" class=\"abstract_t\">49,55-57</a>]. In most cases, the pain is diffuse and nonspecific, although a small minority present with an acute abdomen secondary to perforation or obstruction [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/58\" class=\"abstract_t\">58</a>]. </p><p>The less common localized form of MPM presents as a focal, circumscribed mass that may invade locally and extend into adjacent organs, but typically does not spread diffusely throughout the peritoneal cavity [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Patients may complain of localized abdominal pain or have a palpable abdominal or pelvic mass [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H12630315\"><span class=\"h3\">Pattern of spread</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Morbidity and mortality from MPM are almost invariably due to disease progression within the peritoneal cavity. However, MPM may also extend into the pleural cavity during the latter stages of disease progression, causing a pleural effusion [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/59\" class=\"abstract_t\">59</a>].</p><p>Uncommonly, MPM metastasizes to the abdominal and pelvic lymph nodes. Lymph node metastases are found in approximately 20 to 28 percent of patients undergoing cytoreductive surgery for diffuse MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/60,61\" class=\"abstract_t\">60,61</a>]. Notably, the majority of clinically suspicious lymph nodes are not pathologically positive [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/61\" class=\"abstract_t\">61</a>]. </p><p>Distant metastases are very uncommon [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62-66\" class=\"abstract_t\">62-66</a>]. In a multi-institutional registry-based series of 294 patients with MPM, only 12 had extraabdominal metastases (4 percent) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/66\" class=\"abstract_t\">66</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Paraneoplastic phenomena</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of paraneoplastic phenomena have been described in the setting of mesothelioma, including [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/67-71\" class=\"abstract_t\">67-71</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignancy-related thrombosis (see <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypoglycemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rarely, Coombs-positive hemolytic anemia (see <a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs#H3\" class=\"medical medical_review\">&quot;Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs&quot;, section on 'Antibody detection: the direct Coombs test'</a>)</p><p/><p>The presence of baseline thrombocytosis has been shown to be an independent factor strongly associated with shortened survival in patients with diffuse MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Radiographic imaging</span></p><p class=\"headingAnchor\" id=\"H11317884\"><span class=\"h3\">Diffuse mesothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Computed tomography (CT) is the most useful initial diagnostic study and is typically the first test ordered in a patient with abdominal pain and increasing abdominal girth. The peritoneal masses and nodules may enhance on CT after intravenous injection of iodinated contrast material. However, CT, as with other imaging modalities, tends to underestimate the actual burden of disease. Positron emission tomography (PET scanning) has been used for staging, but it is not reliable for assessing disease extent in MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/73\" class=\"abstract_t\">73</a>].</p><p>The imaging patterns and features of MPM are shown equally well on magnetic resonance imaging (MRI). Limited reports describe the signal intensity of MPM as intermediate to low on T1-weighted images and intermediate to high on T2-weighted images [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/74\" class=\"abstract_t\">74</a>]. More recently, diffusion-weighted and dynamic gadolinium-enhanced MRI have been shown to accurately reflect disease burden in the abdominal cavity both initially and during posttreatment follow-up evaluation of patients with MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/75\" class=\"abstract_t\">75</a>]. MRI may become the primary assessment method in a patient undergoing long-term follow-up evaluation after initial treatment for MPM who cannot receive iodinated contrast or in a woman with a pelvic mass found at clinical examination or ultrasound.</p><p>Diffuse MPM can produce a variety of patterns on cross-sectional imaging:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse and widespread involvement of the peritoneal cavity, tumor infiltration, and <span class=\"nowrap\">irregular/nodular</span> thickening of the peritoneum in a sheet-like fashion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Less commonly, there is a focal pattern of involvement with a dominant intraperitoneal mass with or without associated peritoneal studding [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>]. In some studies, this pattern has been more common with the sarcomatous subtype [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/77\" class=\"abstract_t\">77</a>].</p><p/><p>In addition to the primary tumor, moderate to extensive (rarely massive) ascites is present in 60 to 100 percent of newly diagnosed patients (<a href=\"image.htm?imageKey=ONC%2F73499\" class=\"graphic graphic_diagnosticimage graphicRef73499 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/55,77\" class=\"abstract_t\">55,77</a>]. Other findings include omental <span class=\"nowrap\">caking/thickening,</span> scalloping or direct invasion of intraabdominal organs such as the liver, and diaphragmatic involvement; multiloculated large cystic areas may also be present [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/78\" class=\"abstract_t\">78</a>].</p><p>The sheet-like pattern of growth may extend to the visceral peritoneal surfaces of the small bowel, encasing it and leading to the appearance of a thick intestinal wall on cross sectional images (<a href=\"image.htm?imageKey=ONC%2F58254\" class=\"graphic graphic_diagnosticimage graphicRef58254 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>]. Infiltration of the small bowel mesentery can lead to fixation of the position of the bowel loops and the mesentery, with apparent straightening of the course of the mesenteric vessels [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76,79-81\" class=\"abstract_t\">76,79-81</a>]. These findings, in conjunction with a linearly oriented tumor in the mesentery, produce a characteristic &quot;pleated&quot; appearance on cross-sectional imaging (<a href=\"image.htm?imageKey=ONC%2F74187\" class=\"graphic graphic_diagnosticimage graphicRef74187 \">image 3</a>) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>].</p><p>Calcifications within diffuse MPM are considered rare. Calcified plaques are seen less often than with pleural mesothelioma; however, calcified pleural plaques and other signs associated with asbestos exposure may be present in the chest in up to 50 percent of patients [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/81\" class=\"abstract_t\">81</a>].</p><p>Published frequencies of positive CT findings are summarized in the table (<a href=\"image.htm?imageKey=ONC%2F82228\" class=\"graphic graphic_table graphicRef82228 \">table 1</a>). For patients being considered for aggressive locoregional therapy, results from the initial staging CT scan can be used to predict the likelihood of complete surgical cytoreduction. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment#H135336274\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;, section on 'Cytoreductive surgery and intraperitoneal chemotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Localized mesothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Localized mesothelioma is an uncommon manifestation of the disease. The localized type of MPM appears as a heterogeneous, solid intraperitoneal mass on cross sectional imaging. The margins are often irregular, and there may be scalloping or direct invasion of adjacent visceral structures such as the liver, spleen, or pelvic organs. Localized, loculated ascitic fluid may be present, but manifestations of diffuse peritoneal involvement (generalized ascites, omental caking, and peritoneal nodularity) are characteristically absent [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based on imaging findings, the differential diagnosis for a typical diffuse MPM includes peritoneal carcinomatosis, serous peritoneal carcinoma, ovarian carcinoma in women, lymphomatosis, and tuberculous peritonitis. There are no imaging features that are specific for MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/55\" class=\"abstract_t\">55</a>], although some features may help to suggest a specific diagnosis (see <a href=\"topic.htm?path=abdominal-tuberculosis\" class=\"medical medical_review\">&quot;Abdominal tuberculosis&quot;</a> and <a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver metastases and lymphadenopathy are more common with peritoneal carcinomatosis from gastrointestinal tract primary neoplasms than they are with MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/78\" class=\"abstract_t\">78</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The finding of diffuse adenopathy with a lack of omental involvement should raise suspicion for lymphomatosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculous peritonitis is usually characterized by smooth peritoneal thickening, mesenteric lymphadenopathy with central necrosis, ascites with high attenuation, and splenomegaly.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In women, the main differential is between diffuse MPM and serous carcinoma of the peritoneum [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/80\" class=\"abstract_t\">80</a>]. This entity is a primary neoplasm arising within the peritoneum but is not likely of mesothelial cell origin. Instead, it is considered to arise from ovarian epithelial rests that are a remnant of the ovary's descent into the pelvis. Any of the pelvic adnexa may, in fact, be a source of these cells. These tumors are histologically, immunophenotypically, and clinically distinct from mesothelioma, but similar to epithelial carcinomas of the ovary. (See <a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-histopathology\" class=\"medical medical_review\">&quot;Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two related primary malignancies of the peritoneum with distinctive characteristics on CT are well-differentiated papillary mesothelioma, and multicystic mesothelioma. These tumors are important to distinguish from diffuse peritoneal mesothelioma because their treatment strategy is primarily surgical and the clinical course is largely benign. (See <a href=\"#H8237760\" class=\"local\">'Peritoneal mesothelioma variants'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H11317891\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum chemistries and tumor markers are of no value in establishing a diagnosis of MPM. Elevated levels of hyaluronan, CA-125, alpha-fetoprotein, carcinoembryonic antigen, and mesothelin are found in some patients, and there is often a correlation between elevated levels and disease progression. However, for diagnostic purposes, the specificity of all of these tumor markers is low [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/55,82\" class=\"abstract_t\">55,82</a>].</p><p>Although one study has shown that baseline serum CA-125 has prognostic significance in patients with MPM undergoing operative cytoreduction [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/83\" class=\"abstract_t\">83</a>], this parameter has not been adopted in clinical decision making regarding selection of treatment. CA-125 [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/82\" class=\"abstract_t\">82</a>] and mesothelin may prove useful to follow response to therapy or for posttreatment surveillance if they are initially elevated.</p><p class=\"headingAnchor\" id=\"H11317970\"><span class=\"h3\">Mesothelin and soluble mesothelin-related peptide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mesothelin is a glycoprotein that is expressed on the surface of normal mesothelial cells and highly overexpressed in malignant mesothelioma. Soluble mesothelin-related peptides (SMRPs) are believed to be either cleaved peptide fragments of mesothelin, or abnormal variants of mesothelin that are unable to bind to membranes and are found in the serum. Mesothelin and its associated peptide fragments appear to be of some value as tumor markers in mesothelioma, although limited to the epithelioid and biphasic subtypes. The bulk of the data are in patients with the pleural variant. </p><p>An ELISA is commercially available (Mesomark assay) to measure serum levels of SMRPs that are shed into the circulation in patients with mesothelioma. Lack of sensitivity and specificity limits the utility of this marker for diagnostic purposes [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/84,85\" class=\"abstract_t\">84,85</a>]. As an example, in one report, elevated levels (&ge;9 <span class=\"nowrap\">ng/mL)</span> were seen in 40 of 56 (71 percent) of patients with mesothelioma (primary site not specified), in 13 percent of randomly selected hospitalized patients without a diagnosis of cancer, and in 8 of 21 patients with advanced ovarian cancer [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Serum levels of SRMP are potentially more useful as a marker of disease activity in patients with an established diagnosis [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/84,86\" class=\"abstract_t\">84,86</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">DIAGNOSIS AND HISTOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of peritoneal mesothelioma should be considered in any individual with evidence of a diffuse malignant process in the abdomen on initial clinical and radiographic evaluation, and it can usually be established cytologically or by biopsy. </p><p>In general, cytologic analysis of ascitic fluid is of limited diagnostic utility. Although a diagnosis of mesothelioma can be made cytologically [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/87\" class=\"abstract_t\">87</a>], fluid cytology is often inconclusive and has a low yield [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56,70\" class=\"abstract_t\">56,70</a>]. The differentiation between benign or malignant causes of mesothelial cell proliferation can be especially difficult. Cytology does not allow for assessment of true stromal invasion into the peritoneum or the underlying viscera, the defining parameter of malignancy [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/88\" class=\"abstract_t\">88</a>]. Invasion can only be seen on histologic study of solid tumor material. (See <a href=\"topic.htm?path=malignancy-related-ascites#H21\" class=\"medical medical_review\">&quot;Malignancy-related ascites&quot;, section on 'Cytology'</a>.)</p><p>CT-guided core needle biopsy or laparoscopic biopsy may both provide sufficient material to make a tissue diagnosis. Features seen on hematoxylin and eosin (H&amp;E)-stained sections and immunohistochemical staining characteristics usually allow the differentiation of mesothelioma from other tumors. Because of the propensity for mesothelioma to seed needle tracts or trocar sites [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56\" class=\"abstract_t\">56</a>], the site of the <span class=\"nowrap\">biopsy/laparoscopic</span> port sites are usually excised at the time of surgery. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment#H135336288\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;, section on 'Technique'</a>.) </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Histology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Grossly, malignant peritoneal mesothelioma (MPM) is characterized macroscopically by hundreds to thousands of individual tumor nodules of varying size and consistency that are usually diffusely disseminated throughout the peritoneal cavity (<a href=\"image.htm?imageKey=ONC%2F82141\" class=\"graphic graphic_picture graphicRef82141 \">picture 1</a>). The lesions may range from diffuse subcentimeter gray hard nodules to large nodular masses that spread in sheets and coalesce to form plaques and masses, replacing the omentum, circumferentially encasing the bowels, and invading solid organs, mesentery, and diaphragm. These tumors may have a gelatinous consistency, depending on the <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a> content, and as they progress, they interrupt peritoneal lymphatics and produce exudative fluid from their surfaces, resulting in ascites.</p><p>Histologic examination of routine hematoxylin-eosin stained sections allows the classification of MPM into one of three broad histologic subtypes, epithelioid, sarcomatoid, and biphasic (mixed); the characteristic histological patterns are similar to those encountered in pleural mesothelioma (<a href=\"image.htm?imageKey=ONC%2F59108\" class=\"graphic graphic_picture graphicRef59108 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/89\" class=\"abstract_t\">89</a>]. Tubulopapillary (well-differentiated) mesothelioma, a rare variant that is seen more often in the peritoneum than in the pleura, is discussed below. (See <a href=\"#H8237767\" class=\"local\">'Well-differentiated papillary mesothelioma'</a> below and <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma#H4\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;, section on 'Histology'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epithelioid malignant mesotheliomas are composed of cells that resemble normal mesothelial cells [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"abstract_t\">51</a>]. Architecturally, they form a tubulopapillary or trabecular pattern. Flattened or cuboidal cells with monotonous nuclei line the papilla or tubules. Mitotic figures are uncommon. The tumor infiltrates submesothelial connective tissue, fat, <span class=\"nowrap\">and/or</span> muscle. There may be other characteristics, such as signet-ring cell structure or a desmoplastic response, which makes it difficult to distinguish from another adenocarcinoma on histologic analysis alone. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The sarcomatous pattern, which is less common in the peritoneum as compared with the pleura, is typically composed of tightly packed spindle cells. Malignant osteoid, chondroid, or muscular elements may be present within the tumor [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"abstract_t\">51</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A biphasic tumor is defined as one with both epithelioid and sarcomatous components, each contributing more than 10 percent to the overall histology.</p><p/><p>As in the pleura, peritoneal mesotheliomas with a sarcomatoid component have a worse prognosis [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56,90,91\" class=\"abstract_t\">56,90,91</a>]. In one report, the median survival for the epithelioid subgroups of MPM was 55 months, compared with 13 months for the combined sarcomatoid and biphasic subtypes [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56\" class=\"abstract_t\">56</a>].</p><p>The distinction between benign and malignant mesothelial proliferations is sometimes challenging:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologic evidence of invasion is the defining parameter in the distinction between malignant or benign mesothelial proliferations. However, even in biopsy or surgical specimens, mesothelial cells are frequently subject to entrapment in adhesions, fat lobules and inflammatory tissue that may falsely suggest stromal invasion. In particular, the pelvic adnexa are notorious for granulomatous and adhesive mesothelial entrapment, due to the intense inflammatory conditions that frequent this part of the anatomy. Also, cells in ascites can sediment onto a mesothelial surface which, when biopsied, resembles a mesothelial proliferation that has subserosal invasion [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/88\" class=\"abstract_t\">88</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atypia and necrosis are more common in malignant tumors but are neither sufficiently sensitive nor specific for distinguishing between benign and malignant mesothelium.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A promising but still new area of investigation that may help to differentiate benign from malignant mesothelium is immunohistochemical labeling of telomerase. (See <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma#H5\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;, section on 'Immunohistochemistry'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Immunohistochemistry</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although immunohistochemical staining (IHC) for several markers can assist in identifying mesothelial cells, none is specific for mesothelioma. Instead, a panel of markers is generally used to help differentiate a mesothelioma from more common tumors, such as metastatic adenocarcinoma, peritoneal serous carcinoma, and soft tissue sarcoma, which might have a similar histologic appearance [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76,80,92,93\" class=\"abstract_t\">76,80,92,93</a>]. The most useful of these are summarized below (see <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma#H5\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;, section on 'Immunohistochemistry'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast to adenocarcinomas, MPM produces large amounts of <a href=\"topic.htm?path=hyaluronate-derivatives-drug-information\" class=\"drug drug_general\">hyaluronic acid</a>, and the distinction can be easily made with the use of colloidal iron or alcian blue and hyaluronidase.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another differentiating feature is the presence or absence of neutral mucin as determined by the periodic acid Schiff (PAS) stain and diastase; MPM is invariably devoid of neutral mucin [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/94-96\" class=\"abstract_t\">94-96</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mesotheliomas usually stain negative for other adenocarcinoma markers, including CEA, LeuM1, Ber-Ep4, B72.3, Bg8, PAX-8, and MOC-31.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most mesotheliomas stain positively for calretinin, cytokeratins <span class=\"nowrap\">5/6,</span> Wilms tumor-1 (WT-1), the epidermal growth factors receptor (EGFR), CA125, thrombomodulin, and mesothelin. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Staining patterns appear to be similar across histologic subtypes. In a histologic study of 64 tumors of various subtypes, CA125 was positive in 94 percent, EGFR in 94 percent, and calretinin in 93 percent. Tumors also stained positive for p16 in 85 percent, cytokeratin <span class=\"nowrap\">5/6</span> in 76 percent, D2-40 in 71 percent, and WT-1 in 47 percent [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/97\" class=\"abstract_t\">97</a>].</p><p/><p>Overall, IHC staining for cytokeratin <span class=\"nowrap\">5/6,</span> calretinin and WT-1 (positive markers for mesothelioma), and CEA, Ber-Ep4, LeuM1 and Bg8 (negative in mesothelioma) represents the most helpful panel of markers for MPM [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76,80,89\" class=\"abstract_t\">76,80,89</a>]. The use of at least two mesothelioma markers and two carcinoma markers is recommended [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/89\" class=\"abstract_t\">89</a>]. </p><p>Occasionally, when an epithelioid mesothelioma is extremely dedifferentiated or if it is a desmoplastic variant, ultrastructural analysis via electron microscopy may be beneficial, although it is rarely needed. Among patients who have a peritoneal primary tumor, electron microscopy is less helpful for the differentiation of a sarcomatous mesothelioma from a soft tissue sarcoma [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma#H6\" class=\"medical medical_review\">&quot;Pathology of malignant pleural mesothelioma&quot;, section on 'Electron microscopy'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">STAGING AND THE STAGING WORKUP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no uniformly accepted staging system for malignant peritoneal mesothelioma (MPM). The peritoneal cancer index, which is derived from radiographic imaging and intraoperative evaluation, is discussed elsewhere. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment#H135336281\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;, section on 'Patient selection'</a>.)</p><p>Because of the low frequency of disease spread outside of the peritoneum, a staging evaluation for distant metastases is generally not needed, unless there are symptoms suggesting metastases to a distant organ. For patients who present with a pleural effusion, further diagnostic testing with thoracentesis or video-assisted thoracoscopic surgery (VATS) is important to eliminate the possibility of tumor spread into the pleural cavity, which might alter the therapeutic approach. A novel tumor, node, metastasis or &quot;TNM&quot; staging system has been proposed that takes into account the extent of disease in the peritoneum (T stage), the presence of intra-abdominal lymph node metastases (N), and the absence or presence of extra-abdominal disease (M) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/66\" class=\"abstract_t\">66</a>]. T stage is calculated based on the peritoneal cancer index (PCI [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/98\" class=\"abstract_t\">98</a>]), a measure of the volume and extent of tumor deposits as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T1 &ndash; PCI 1-10</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T2 &ndash; PCI 11-20</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T3 &ndash; PCI 21-30</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T4 &ndash; PCI 31-39 </p><p/><p> Stage groupings, which were associated with a progressive decrease in survival, were as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage I &ndash; T1 N0 M0; five-year survival 87 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage II &ndash; T2-3 N0 M0; five-year survival 53 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage III &ndash; T4 N0-1 M0, T1-4 N1 M01-, and T1-4 N0-1 M1; five-year survival 29 percent</p><p/><p>(See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8237760\"><span class=\"h1\">PERITONEAL MESOTHELIOMA VARIANTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are two rare variants of peritoneal mesothelioma. Both are characterized by indolent behavior and the potential for malignant transformation to malignant peritoneal mesothelioma (MPM).</p><p class=\"headingAnchor\" id=\"H8237767\"><span class=\"h2\">Well-differentiated papillary mesothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Well-differentiated papillary mesothelioma is a rare clinicopathologic entity that is distinct from MPM. It occurs predominantly in women of reproductive age and most often arises from the peritoneal surfaces of the pelvis [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"abstract_t\">76</a>]. There is no reported association with asbestos exposure [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/99\" class=\"abstract_t\">99</a>].</p><p>These indolent tumors are small (most &lt;2 cm) and typically identified as an incidental finding at surgery performed for another indication [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/100-102\" class=\"abstract_t\">100-102</a>]. On histologic analysis, the tumors have a well-developed papillary architecture with uniform, flat or cuboidal epithelium lining the papilla. Invasion is absent. These tumors must be differentiated from ordinary diffuse MPM with focal papillary architecture [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The radiologic appearance is rarely described. There may be plaque-like calcification that diffusely involves the visceral and parietal peritoneum without the presence of an associated soft tissue mass [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/103\" class=\"abstract_t\">103</a>]. Rarely, there is peritoneal thickening, multiple peritoneal nodules, omental infiltration, <span class=\"nowrap\">and/or</span> ascites.</p><p>Well-differentiated papillary mesothelioma is generally considered a low-grade malignancy, with a high rate of cure following complete surgical resection, although long-term follow-up is required because of the potential to recur and progress to true MPM. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment#H135336358\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;, section on 'Well-differentiated papillary mesothelioma'</a>.)</p><p class=\"headingAnchor\" id=\"H8237774\"><span class=\"h2\">Multicystic mesothelioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multicystic mesothelioma is an unusual cystic tumor that most commonly arises from the pelvic peritoneal surfaces in young and middle-aged women [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51,104-106\" class=\"abstract_t\">51,104-106</a>]. Men represent only 17 percent of cases [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/105\" class=\"abstract_t\">105</a>]. There is no association with asbestos exposure.</p><p>There is ongoing debate as to the origin of this lesion. This controversy is reflected in the variety of names used to describe this entity, including multicystic mesothelioma (the predominant terminology used), cystic mesothelioma, benign cystic mesothelioma, and peritoneal inclusion cyst. Many women have a history of prior pelvic surgery, endometriosis, or pelvic inflammatory disease, which some consider support for classification as a reactive mesothelial proliferation. Furthermore, the histologic appearance is bland and the biologic behavior is indolent, despite the high rate of recurrence after surgical treatment (up 50 percent) [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/104\" class=\"abstract_t\">104</a>]. The presence of this lesion has not altered patient survival in the vast majority of cases. However, local recurrences are frequent, leading to morbidity [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/107\" class=\"abstract_t\">107</a>], and there have been isolated reports of malignant transformation to aggressive diffuse malignant mesothelioma, a finding that tends to favor (but does not prove) a neoplastic rather than reactive origin [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51,105,106,108,109\" class=\"abstract_t\">51,105,106,108,109</a>].</p><p>The majority of cases present with chronic or intermittent lower abdominal or pelvic pain [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/107\" class=\"abstract_t\">107</a>]. Occasionally, the diagnosis is made incidentally at surgery or on ultrasound or cross-sectional imaging:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On ultrasound, there are multiseptated structures that have an intimate anatomic association with the uterus and ovaries [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/107\" class=\"abstract_t\">107</a>]. The fluid within the cysts is usually anechoic.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On CT or MRI scan, the cysts have fluid attenuation values, and the septae enhance with IV iodinated contrast and gadolinium [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/74,107\" class=\"abstract_t\">74,107</a>]. There may be thick-walled cysts that appear as soft tissue attenuation lesions [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/110\" class=\"abstract_t\">110</a>].</p><p/><p>The main differential diagnosis is with cystic lymphangioma, mesenteric or omental cysts, cystic epithelial neoplasms of the ovaries, endometriosis, malignant mesothelioma, and pseudomyxoma peritonei.</p><p>Pathologically, these tumors are large (mean size at diagnosis 13 cm) and consist of multiple grape-like clusters of mesothelium-lined cysts that grow along the pelvic peritoneum [<a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76,111\" class=\"abstract_t\">76,111</a>].</p><p>Although the disease is well characterized histologically, the pathogenesis, natural history, and clinical management are not well defined. The clinical course is usually indolent, and surgical resection can be curative. However, as with the well-differentiated papillary mesothelioma, long-term follow-up is needed, since local recurrence can occur in up to 50 percent from 1 to 27 years after initial diagnosis, and malignant transformation is rarely reported. (See <a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment#H135336365\" class=\"medical medical_review\">&quot;Malignant peritoneal mesothelioma: Treatment&quot;, section on 'Multicystic mesothelioma'</a>.)</p><p class=\"headingAnchor\" id=\"H38\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum and spreads rapidly within the confines of the abdominal cavity. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As with mesothelioma arising in other sites, there is a strong relationship between asbestos exposure and the development of MPM. However, the link between exposure to asbestos and peritoneal mesothelioma is less strong than it is for pleural mesothelioma, particularly among women. A germline BRCA-associated protein (BAP) 1 mutation may predispose individuals to develop MPM. (See <a href=\"#H2\" class=\"local\">'Epidemiology and risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The majority of cases of MPM present with diffuse peritoneal involvement. Common complaints include abdominal distention <span class=\"nowrap\">and/or</span> increasing abdominal girth, abdominal pain, nausea, anorexia, and weight loss. Rarely, patients present with a paraneoplastic syndrome (fever, thrombocytosis, hypoglycemia). (See <a href=\"#H12630199\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The imaging patterns and features of MPM are shown equally well on CT and magnetic resonance imaging. The pattern of involvement is usually diffuse and widespread involvement of the peritoneal cavity with tumor infiltration and <span class=\"nowrap\">irregular/nodular</span> thickening of the peritoneum in a sheetlike fashion, usually with moderate to extensive ascites. Less commonly, there is a focal pattern of involvement with a dominant intraperitoneal mass with or without associated peritoneal studding. (See <a href=\"#H11\" class=\"local\">'Radiographic imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>None of the radiographic findings is sufficiently specific for MPM to avoid the need for tissue diagnosis. Ascitic fluid cytology is often inconclusive, especially in distinguishing between malignant and benign mesothelial proliferations. CT-guided core needle biopsy or laparoscopic biopsy may provide sufficient material to establish the diagnosis, which usually requires a panel of immunohistochemical stains. (See <a href=\"#H14\" class=\"local\">'Diagnosis and histology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no tumor markers with sufficient sensitivity or specificity to be useful in the diagnostic evaluation of a patient with suspected MPM. (See <a href=\"#H11317891\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no uniformly accepted staging system for MPM. Given the very low risk of extraabdominal spread, a radiographic staging workup is generally not needed in the absence of symptoms. (See <a href=\"#H19\" class=\"local\">'Staging and the staging workup'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are two rare variants of peritoneal mesothelioma, well-differentiated papillary mesothelioma and multicystic mesothelioma (peritoneal inclusion cyst), which are both are characterized by a localized presentation and indolent behavior. (See <a href=\"#H8237760\" class=\"local\">'Peritoneal mesothelioma variants'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/1\" class=\"nounderline abstract_t\">Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008; 17:525.</a></li><li class=\"breakAll\">SEER Cancer Statistics Review - Mesothelioma fast stats. http://seer.cancer.gov/faststats/selections.php?series=cancer (Accessed on April 03, 2012).</li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/3\" class=\"nounderline abstract_t\">Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/4\" class=\"nounderline abstract_t\">Rodr&iacute;guez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol 2009; 99:51.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/5\" class=\"nounderline abstract_t\">L&oacute;pez-R&iacute;os F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66:2970.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/6\" class=\"nounderline abstract_t\">Borczuk AC, Cappellini GC, Kim HK, et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2007; 26:610.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/7\" class=\"nounderline abstract_t\">Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/8\" class=\"nounderline abstract_t\">Watterson A, Gorman T, Malcolm C, et al. The economic costs of health service treatments for asbestos-related mesothelioma deaths. Ann N Y Acad Sci 2006; 1076:871.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/9\" class=\"nounderline abstract_t\">Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009; 39:576.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/10\" class=\"nounderline abstract_t\">Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009; 20:935.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/11\" class=\"nounderline abstract_t\">Hemminki K, Li X. Time trends and occupational risk factors for peritoneal mesothelioma in Sweden. J Occup Environ Med 2003; 45:451.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/12\" class=\"nounderline abstract_t\">Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015; 22:1686.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/13\" class=\"nounderline abstract_t\">Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994; 51:804.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/14\" class=\"nounderline abstract_t\">Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996; 81:193.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/15\" class=\"nounderline abstract_t\">Kaya H, Sezg&#305; C, Tanr&#305;kulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma 2014; 61:433.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/16\" class=\"nounderline abstract_t\">Niggli FK, Gray TJ, Raafat F, Stevens MC. Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry. Pediatr Hematol Oncol 1994; 11:399.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/17\" class=\"nounderline abstract_t\">Moran CA, Albores-Saavedra J, Suster S. Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases. Histopathology 2008; 52:824.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/18\" class=\"nounderline abstract_t\">Cioffredi LA, J&auml;nne PA, Jackman DM. Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer 2009; 52:127.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/19\" class=\"nounderline abstract_t\">Frost G. The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005). Br J Cancer 2013; 109:1965.</a></li><li class=\"breakAll\">Abos-Herrandiz R, Rodriguez-Blanco T, Garcia Allas I, et al. Risk factors of mortality from all asbestos-related diseases: a completing Risk Analysis. Canad Resp J 2017; article ID 9015914. PDF available online at https://www.hindawi.com/journals/crj/2017/9015914/ (Accessed on November 16, 2017).</li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/21\" class=\"nounderline abstract_t\">Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 1995; 19:1124.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/22\" class=\"nounderline abstract_t\">Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002; 94:378.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/23\" class=\"nounderline abstract_t\">Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002; 26:55.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/24\" class=\"nounderline abstract_t\">Cocco P, Dosemeci M. Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix. Am J Ind Med 1999; 35:9.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/25\" class=\"nounderline abstract_t\">Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. 1965. Br J Ind Med 1993; 50:769.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/26\" class=\"nounderline abstract_t\">Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978; 1:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/27\" class=\"nounderline abstract_t\">Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44:565.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/28\" class=\"nounderline abstract_t\">McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 1980; 46:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/29\" class=\"nounderline abstract_t\">Berry G, Reid A, Aboagye-Sarfo P, et al. Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up. Br J Cancer 2012; 106:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/30\" class=\"nounderline abstract_t\">Alakus H, Yost SE, Woo B, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015; 13:122.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/31\" class=\"nounderline abstract_t\">Napolitano A, Pellegrini L, Dey A, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2016; 35:1996.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/32\" class=\"nounderline abstract_t\">Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol 2001; 27:214.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/33\" class=\"nounderline abstract_t\">Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol 1996; 14:2098.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/34\" class=\"nounderline abstract_t\">Antman KH, Corson JM, Li FP, et al. Malignant mesothelioma following radiation exposure. J Clin Oncol 1983; 1:695.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/35\" class=\"nounderline abstract_t\">Farioli A, Ottone M, Morganti AG, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med 2016; 5:950.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/36\" class=\"nounderline abstract_t\">Baris I, Simonato L, Artvinli M, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987; 39:10.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/37\" class=\"nounderline abstract_t\">Andersson M, Wallin H, J&ouml;nsson M, et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int J Cancer 1995; 63:330.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/38\" class=\"nounderline abstract_t\">van Kaick G, Dalheimer A, Hornik S, et al. The german thorotrast study: recent results and assessment of risks. Radiat Res 1999; 152:S64.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/39\" class=\"nounderline abstract_t\">Ishikawa Y, Mori T, Machinami R. Lack of apparent excess of malignant mesothelioma but increased overall malignancies of peritoneal cavity in Japanese autopsies with Thorotrast injection into blood vessels. J Cancer Res Clin Oncol 1995; 121:567.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/40\" class=\"nounderline abstract_t\">Shivapurkar N, Wiethege T, Wistuba II, et al. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer 2000; 85:743.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/41\" class=\"nounderline abstract_t\">Rivera Z, Strianese O, Bertino P, et al. The relationship between simian virus 40 and mesothelioma. Curr Opin Pulm Med 2008; 14:316.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/42\" class=\"nounderline abstract_t\">Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 1981; 48:134.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/43\" class=\"nounderline abstract_t\">Gentiloni N, Febbraro S, Barone C, et al. Peritoneal mesothelioma in recurrent familial peritonitis. J Clin Gastroenterol 1997; 24:276.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/44\" class=\"nounderline abstract_t\">Schiffman MH, Pickle LW, Fontham E, et al. Case-control study of diet and mesothelioma in Louisiana. Cancer Res 1988; 48:2911.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/45\" class=\"nounderline abstract_t\">Leblay N, Lepr&ecirc;tre F, Le Stang N, et al. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of&nbsp;Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017; 12:724.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/46\" class=\"nounderline abstract_t\">Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol 2016; 29:14.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/47\" class=\"nounderline abstract_t\">Hung YP, Dong F, Watkins JC, et al. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol 2018; 4:235.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/48\" class=\"nounderline abstract_t\">Sugarbaker PH, Yan H, Grazi RV, Shmookler BM. Early localized peritoneal mesothelioma as an incidental finding at laparoscopy. Report of a case and implications regarding natural history of the disease. Cancer 2000; 89:1279.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/49\" class=\"nounderline abstract_t\">Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8:313.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/50\" class=\"nounderline abstract_t\">Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/51\" class=\"nounderline abstract_t\">Levy AD, Arn&aacute;iz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 2008; 28:583.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/52\" class=\"nounderline abstract_t\">D'Abbicco D, Conversano A, Epifania BR, et al. Splenic localization of the peritoneal mesothelioma: case report and literature revue. Updates Surg 2012; 64:157.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/53\" class=\"nounderline abstract_t\">Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/54\" class=\"nounderline abstract_t\">Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/55\" class=\"nounderline abstract_t\">Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/56\" class=\"nounderline abstract_t\">Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/57\" class=\"nounderline abstract_t\">van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989; 43:222.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/58\" class=\"nounderline abstract_t\">Salemis NS, Tsiambas E, Gourgiotis S, et al. Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation. J Dig Dis 2007; 8:216.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/59\" class=\"nounderline abstract_t\">Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014; 21:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/60\" class=\"nounderline abstract_t\">Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/61\" class=\"nounderline abstract_t\">Baratti D, Kusamura S, Cabras AD, et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010; 17:45.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/62\" class=\"nounderline abstract_t\">Pappa L, Machera M, Tsanou E, et al. Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration. Pathol Oncol Res 2006; 12:247.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/63\" class=\"nounderline abstract_t\">Ord&oacute;&ntilde;ez NG, Smith JL Jr. Peritoneal malignant mesothelioma with multiple distant skin metastases. Arch Dermatol 1983; 119:827.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/64\" class=\"nounderline abstract_t\">Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2009; 16:463.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/65\" class=\"nounderline abstract_t\">Roberts GH. Distant visceral metastases in pleural mesothelioma. Br J Dis Chest 1976; 70:246.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/66\" class=\"nounderline abstract_t\">Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 2011; 117:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/67\" class=\"nounderline abstract_t\">de Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori 2005; 91:1.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/68\" class=\"nounderline abstract_t\">Ust&uuml;nda&#287; Y, Can U, Benli S, et al. Internal carotid artery occlusion in a patient with malignant peritoneal mesothelioma: is it a sign of malignancy-related thrombosis? Am J Med Sci 2000; 319:265.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/69\" class=\"nounderline abstract_t\">Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/70\" class=\"nounderline abstract_t\">Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010; 21:348.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/71\" class=\"nounderline abstract_t\">Selleslag DL, Geraghty RJ, Ganesan TS, et al. Autoimmune haemolytic anaemia associated with malignant peritoneal mesothelioma. Acta Clin Belg 1989; 44:199.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/72\" class=\"nounderline abstract_t\">Li YC, Khashab T, Terhune J, et al. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2017; 24:2259.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/73\" class=\"nounderline abstract_t\">Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98:268.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/74\" class=\"nounderline abstract_t\">Szklaruk J, Tamm EP, Choi H, Varavithya V. MR imaging of common and uncommon large pelvic masses. Radiographics 2003; 23:403.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/75\" class=\"nounderline abstract_t\">Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2012; 19:1394.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/76\" class=\"nounderline abstract_t\">Takeshima Y, Amatya VJ, Kushitani K, Inai K. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 2008; 130:771.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/77\" class=\"nounderline abstract_t\">Ros PR, Yuschok TJ, Buck JL, et al. Peritoneal mesothelioma. Radiologic appearances correlated with histology. Acta Radiol 1991; 32:355.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/78\" class=\"nounderline abstract_t\">Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008; 191:814.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/79\" class=\"nounderline abstract_t\">Yan TD, Haveric N, Carmignani CP, et al. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 2005; 91:394.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/80\" class=\"nounderline abstract_t\">Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007; 31:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/81\" class=\"nounderline abstract_t\">Guest PJ, Reznek RH, Selleslag D, et al. Peritoneal mesothelioma: the role of computed tomography in diagnosis and follow up. Clin Radiol 1992; 45:79.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/82\" class=\"nounderline abstract_t\">Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2007; 14:500.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/83\" class=\"nounderline abstract_t\">Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 2013; 20:555.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/84\" class=\"nounderline abstract_t\">Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12:447.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/85\" class=\"nounderline abstract_t\">Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30:1541.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/86\" class=\"nounderline abstract_t\">Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28:3316.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/87\" class=\"nounderline abstract_t\">Patel NP, Taylor CA, Levine EA, et al. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol 2007; 128:414.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/88\" class=\"nounderline abstract_t\">Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/89\" class=\"nounderline abstract_t\">Husain AN, Colby TV, Ord&oacute;&ntilde;ez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142:89.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/90\" class=\"nounderline abstract_t\">Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008; 31:49.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/91\" class=\"nounderline abstract_t\">Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014; 46:604.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/92\" class=\"nounderline abstract_t\">Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: how useful are the &quot;newer&quot; markers in body fluid cytology? Arch Pathol Lab Med 2008; 132:23.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/93\" class=\"nounderline abstract_t\">Onofre FB, Onofre AS, Pomjanski N, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008; 114:204.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/94\" class=\"nounderline abstract_t\">Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14:447.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/95\" class=\"nounderline abstract_t\">Suzuki Y. Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn 1992; 42:767.</a></li><li class=\"breakAll\">Peritoneum, Preperitoneum, and Related Structures. In: Rosai and Ackerman's Surgical Pathology, 9th, Rosai J (Ed), Mosby, 2004.</li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/97\" class=\"nounderline abstract_t\">Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy. Pathology 2013; 45:464.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/98\" class=\"nounderline abstract_t\">Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82:359.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/99\" class=\"nounderline abstract_t\">Hoekman K, Tognon G, Risse EK, et al. Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Eur J Cancer 1996; 32A:255.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/100\" class=\"nounderline abstract_t\">Hoekstra AV, Riben MW, Frumovitz M, et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98:161.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/101\" class=\"nounderline abstract_t\">Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 1990; 65:292.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/102\" class=\"nounderline abstract_t\">Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol 2001; 25:1304.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/103\" class=\"nounderline abstract_t\">Lovell FA, Cranston PE. Well-differentiated papillary mesothelioma of the peritoneum. AJR Am J Roentgenol 1990; 155:1245.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/104\" class=\"nounderline abstract_t\">Katsube Y, Mukai K, Silverberg SG. Cystic mesothelioma of the peritoneum: a report of five cases and review of the literature. Cancer 1982; 50:1615.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/105\" class=\"nounderline abstract_t\">Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988; 12:737.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/106\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of &quot;benign&quot; cystic mesothelioma of the peritoneum. J Surg Oncol 2002; 79:243.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/107\" class=\"nounderline abstract_t\">Vallerie AM, Lerner JP, Wright JD, Baxi LV. Peritoneal inclusion cysts: a review. Obstet Gynecol Surv 2009; 64:321.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/108\" class=\"nounderline abstract_t\">Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005; 123:724.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/109\" class=\"nounderline abstract_t\">DeStephano DB, Wesley JR, Heidelberger KP, et al. Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case. Pediatr Pathol 1985; 4:291.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/110\" class=\"nounderline abstract_t\">Sugarbaker P, Yan T, Zappa L, et al. Thin-walled cysts as a pathognomonic CT finding in cystic mesothelioma. Tumori 2008; 94:14.</a></li><li><a href=\"https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging/abstract/111\" class=\"nounderline abstract_t\">Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics 2005; 25:983.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2504 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H38\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY AND RISK FACTORS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Risk factors</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Asbestos</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Radiation therapy</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Other factors</a></li></ul></li></ul></li><li><a href=\"#H1274984149\" id=\"outline-link-H1274984149\">MOLECULAR PATHOGENESIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">CLINICAL PRESENTATION AND IMAGING FEATURES</a><ul><li><a href=\"#H12630199\" id=\"outline-link-H12630199\">Clinical features</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Diffuse versus localized peritoneal mesothelioma</a></li><li><a href=\"#H12630315\" id=\"outline-link-H12630315\">- Pattern of spread</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Paraneoplastic phenomena</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">Radiographic imaging</a><ul><li><a href=\"#H11317884\" id=\"outline-link-H11317884\">- Diffuse mesothelioma</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Localized mesothelioma</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Differential diagnosis</a></li></ul></li><li><a href=\"#H11317891\" id=\"outline-link-H11317891\">Laboratory findings</a><ul><li><a href=\"#H11317970\" id=\"outline-link-H11317970\">- Mesothelin and soluble mesothelin-related peptide</a></li></ul></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">DIAGNOSIS AND HISTOLOGY</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">Histology</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">- Immunohistochemistry</a></li></ul></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">STAGING AND THE STAGING WORKUP</a></li><li><a href=\"#H8237760\" id=\"outline-link-H8237760\">PERITONEAL MESOTHELIOMA VARIANTS</a><ul><li><a href=\"#H8237767\" id=\"outline-link-H8237767\">Well-differentiated papillary mesothelioma</a></li><li><a href=\"#H8237774\" id=\"outline-link-H8237774\">Multicystic mesothelioma</a></li></ul></li><li><a href=\"#H38\" id=\"outline-link-H38\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/2504|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/73499\" class=\"graphic graphic_diagnosticimage\">- CT imaging findings</a></li><li><a href=\"image.htm?imageKey=ONC/58254\" class=\"graphic graphic_diagnosticimage\">- MPM 55yr man</a></li><li><a href=\"image.htm?imageKey=ONC/74187\" class=\"graphic graphic_diagnosticimage\">- MPM 73yr man</a></li></ul></li><li><div id=\"ONC/2504|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/82141\" class=\"graphic graphic_picture\">- Gross appearance MPM</a></li><li><a href=\"image.htm?imageKey=ONC/59108\" class=\"graphic graphic_picture\">- H and E subtypes MPM</a></li></ul></li><li><div id=\"ONC/2504|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/82228\" class=\"graphic graphic_table\">- CT findings MPM</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=abdominal-tuberculosis\" class=\"medical medical_review\">Abdominal tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Epidemiology of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-clinical-features-and-diagnosis\" class=\"medical medical_review\">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-histopathology\" class=\"medical medical_review\">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Initial management of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignancy-related-ascites\" class=\"medical medical_review\">Malignancy-related ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignant-peritoneal-mesothelioma-treatment\" class=\"medical medical_review\">Malignant peritoneal mesothelioma: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-autoimmune-hemolytic-anemia-warm-agglutinins-and-drugs\" class=\"medical medical_review\">Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Pathology of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=presentation-initial-evaluation-and-prognosis-of-malignant-pleural-mesothelioma\" class=\"medical medical_review\">Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">Risk and prevention of venous thromboembolism in adults with cancer</a></li></ul></div></div>","javascript":null}